Catalent's Meteoric Rise as Novo Holdings Makes Groundbreaking Acquisition

In a landmark move within the life sciences sector, Novo Holdings has announced its acquisition of Catalent, Inc. in an all-cash transaction valued at $16....

February 08, 2024 | Thursday | News
Navidea Biopharmaceuticals, Inc. Gets $7.5M Cash from Cardinal Health Instead of Milestone Payment

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precis...

June 20, 2023 | Tuesday | News
Researchers Reveal Newfound DNA Repair Mechanism

Published online May 16 in the journal Cell, the report describes the molecular mechanism behind a DNA repair pathway that counters the mistaken inclusion ...

May 18, 2023 | Thursday | News
REGENXBIO's NAV® Technology Platform to Support Bespoke Gene Therapy Consortium's Rare Disease Clinical Portfolio

Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development...

May 17, 2023 | Wednesday | News
Thermo Fisher and Pfizer join forces to expand Cancer Testing in Global Markets

Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...

May 10, 2023 | Wednesday | News
SomaLogic Launches Proteomics Grant Program for APAC Researchers

SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. T...

May 08, 2023 | Monday | News
Unleashing The Potential of Immunology To Improve Public Health

Largely driven by increasing incidence of chronic and infectious diseases and growth in biotechnology and pharma industries, the global immunoassay market ...

May 05, 2023 | Friday | News
Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...

May 05, 2023 | Friday | News
Sapience Therapeutics Awarded $2M Grant to Evaluate Therapeutic Potential of ST316, a First-in-Class Antagonist.

The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impac...

May 05, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in